Sex differences in the cardiovascular consequences of diabetes mellitus a scientific statement from the American Heart Association

Circulation

Volumn 132, Issue 25, 2015, Pages 2424-2447

  Regensteiner, Judith G ^a   Golden, Sherita ^b   Anton, Blair ^c   Barrett Connor, Elizabeth ^d   Chang, Alice Y ^e   Chyun, Deborah ^f   Fox, Caroline S ^g   Huebschmann, Amy G ^a   Kim, Catherine ^h   Mehta, Nehal ^g   Reckelhoff, Jane F ⁱ   Reusch, Jane E B ^j   Rexrode, Kathryn M ^k   Sumner, Anne E ^l   Welty, Francine K ^m   Wenger, Nanette K ⁿ  

^a UNIVERSITY OF COLORADO   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MAYO CLINIC   (United States)

^f NEW YORK UNIVERSITY   (United States)

^g NHLBI   (United States)

^h UNIVERSITY OF MICHIGAN   (United States)

ⁱ UNIVERSITY OF MISSISSIPPI   (United States)

^j UNIVERSITY OF COLORADO   (United States)

^k BRIGHAM AND WOMEN S HOSPITAL   (United States)

^l NATIONAL INSTITUTES OF HEALTH   (United States)

^m BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

ⁿ EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

AHA scientific statements; Diabetes mellitus; Drug therapy; Gonadal steroid hormones; Health behavior; Heart diseases; Pregnancy in diabetics; Women's health

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ORAL ANTIDIABETIC AGENT; RENIN INHIBITOR; SPIRONOLACTONE;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CORONARY RISK; CULTURAL FACTOR; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; ETHNIC GROUP; GLYCEMIC CONTROL; HEART FAILURE; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; MEDICAL SOCIETY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OVARY POLYCYSTIC DISEASE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; RACE DIFFERENCE; RISK FACTOR; SEX DIFFERENCE; BLOOD; CARDIOVASCULAR DISEASES; FEMALE; MALE; SEXUAL DEVELOPMENT; UNITED STATES;

AMERICAN HEART ASSOCIATION; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; FEMALE; HUMANS; MALE; SEX CHARACTERISTICS; UNITED STATES;

EID: 84953336637     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIR.0000000000000343     Document Type: Article

References (297)

1. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States. Atlanta, GA: Centers for Disease Control and Prevention; 2014.
2. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States. Atlanta, GA: Centers for Disease Control and Prevention; 2011.
3. Diabetes in America. 2nd ed. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1995.
4. Kannel WB, Wilson PW Risk factors that attenuate the female coronary disease advantage. Arch Intern Med. 1995; 155:57-61.
5. Hu G, Jousilahti P, Qiao Q., Katoh S, Tuomilehto J. Sex differences in cardiovascular and total mortality among diabetic and non-diabetic individuals with or without history of myocardial infarction. Diabetologia. 2005; 48:856-861. doi:10.1007/s00125-005-1730-6.
6. Gouni-Berthold I., Berthold HK, Mantzoros C.S., Böhm M, Krone W. Sex disparities in the treatment and control of cardiovascular risk factors in type 2 diabetes. Diabetes Care. 2008; 31:1389-1391. doi:10.2337/dc08-0194.
7. Tunstall-Pedoe H. Myth and paradox of coronary risk and the menopause. Lancet. 1998; 351:1425-1427. doi:10.1016/S0140-6736(97)11321-6.
8. Barrett-Connor E.L., Cohn BA, Wingard D.L., Edelstein SL. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study [published correction appears in JAMA. 1991; 265:3249].
9. JAMA. 1991; 265:627-631.
10. Barrett-Connor E., Wingard DL Sex differential in ischemic heart disease mortality in diabetics: a prospective population-based study. Am J Epidemiol. 1983; 118:489-496.
11. Barrett-Connor E. The Rancho Bernardo Study: 40 years studying why women have less heart disease than men and how diabetes modifies women's usual cardiac protection. Glob Heart. 2013; 8(2). doi:10.1016/j. gheart.2012.12.002.
12. Golden SH, Dobs AS, Vaidya D, Szklo M., Gapstur S, Kopp P, Liu K., Ouyang P. Endogenous sex hormones and glucose tolerance status in postmenopausal women. J Clin Endocrinol Metab. 2007; 92:1289-1295. doi:10.1210/jc.2006-1895.
13. Kalish GM, Barrett-Connor E, Laughlin G.A., Gulanski BI; Postmenopausal Estrogen/Progestin Intervention Trial. Association of endogenous sex hormones and insulin resistance among postmenopausal women: results from the Postmenopausal Estrogen/Progestin Intervention Trial. J Clin Endocrinol Metab. 2003; 88:1646-1652. doi:10.1210/jc.2002-021375.
14. Oh JY, Barrett-Connor E, Wedick N.M., Wingard DL; Rancho Bernardo Study. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo Study. Diabetes Care. 2002; 25:55-60.
15. Kanaya AM, Grady D, Barrett-Connor E. Explaining the sex difference in coronary heart disease mortality among patients with type 2 diabetes mellitus: a meta-analysis. Arch Intern Med. 2002; 162:1737-1745.
16. Crandall CJ, Barrett-Connor E. Endogenous sex steroid levels and cardiovascular disease in relation to the menopause: a systematic review. Endocrinol Metab Clin North Am. 2013; 42:227-253. doi:10.1016/j. ecl.2013.02.003.
17. Golden SH, Brown A, Cauley J.A., Chin MH, Gary-Webb TL, Kim C, Sosa J.A., Sumner AE, Anton B. Health disparities in endocrine disorders: biological, clinical, and nonclinical factors: an Endocrine Society scientific statement. J Clin Endocrinol Metab. 2012; 97:E1579-E1639. doi:10.1210/jc.2012-2043.
18. Williams DR. Race and health: basic questions, emerging directions. Ann Epidemiol. 1997; 7:322-333.
19. Age-Adjusted Percentage of People with Diabetes Aged 35 Years or Older Reporting Heart Disease or Stroke, by Race/Ethnicity, United States, 1997-2011. Atlanta, GA: Centers for Disease Control and Prevention; 2012.
20. Lanting LC, Joung IM, Mackenbach J.P., Lamberts SW, Bootsma AH. Ethnic differences in mortality, end-stage complications, and quality of care among diabetic patients: a review. Diabetes Care. 2005; 28:2280-2288.
21. Dagogo-Jack S. Ethnic disparities in type 2 diabetes: pathophysiology and implications for prevention and management. J Natl Med Assoc. 2003; 95:774, 779-789.
22. O'Connell J., Yi R, Wilson C., Manson SM, Acton KJ. Racial disparities in health status: a comparison of the morbidity among American Indian and U.S. adults with diabetes. Diabetes Care. 2010; 33:1463-1470. doi:10.2337/dc09-1652.
23. Tofler GH, Stone PH, Muller J.E., Willich SN, Davis VG, Poole WK, Strauss H.W., Willerson JT, Jaffe AS, Robertson T, Passamani E., Braunwald E. Effects of gender and race on prognosis after myocardial infarction: adverse prognosis for women, particularly black women. J Am Coll Cardiol. 1987; 9:473-482.
24. Wade AN, Fedyna S, Mehta N.N., St Clair C, Ginwala N, Krishna R.K., Qasim AN, Braunstein S, Iqbal N, Schutta M.H., Reilly MP. Type 2 diabetes does not attenuate racial differences in coronary calcification. Diabetes Res Clin Pract. 2011; 91:101-107. doi:10.1016/j.diabres.2010.07.004.
25. Register TC, Divers J, Bowden D.W., Carr JJ, Lenchik L, Wagenknecht LE, Hightower R.C., Xu J., Smith SC, Hruska KA, Langefeld CD, Freedman BI Relationships between serum adiponectin and bone density, adiposity and calcified atherosclerotic plaque in the African American-Diabetes Heart Study. J Clin Endocrinol Metab. 2013; 98:1916-1922. doi:10.1210/jc.2012-4126.
26. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006; 332:73-78. doi:10.1136/bmj.38678.389583.7C.
27. Natarajan S, Liao Y, Cao G., Lipsitz SR, McGee DL. Sex differences in risk for coronary heart disease mortality associated with diabetes and established coronary heart disease. Arch Intern Med. 2003; 163:1735-1740. doi:10.1001/archinte.163.14.1735.
28. Ogden CL, Carroll MD, Kit B.K., Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA. 2014; 311:806-814. doi:10.1001/jama.2014.732.
29. Fujimoto W.Y., Bergstrom RW, Boyko E.J., Chen KW, Leonetti DL, Newell-Morris L, Shofer JB, Wahl PW Visceral adiposity and incident coronary heart disease in Japanese-American men: the 10-year follow-up results of the Seattle Japanese-American Community Diabetes Study. Diabetes Care. 1999; 22:1808-1812.
30. Hayashi T, Boyko EJ, Leonetti D.L., McNeely MJ, Newell-Morris L, Kahn SE, Fujimoto WY Visceral adiposity and the risk of impaired glucose tolerance: a prospective study among Japanese Americans. Diabetes Care. 2003; 26:650-655.
31. Hayashi T, Boyko EJ, McNeely M.J., Leonetti DL, Kahn SE, Fujimoto WY. Visceral adiposity, not abdominal subcutaneous fat area, is associated with an increase in future insulin resistance in Japanese Americans. Diabetes. 2008; 57:1269-1275. doi:10.2337/db07-1378.
32. Katzmarzyk PT, Heymsfield SB, Bouchard C. Clinical utility of visceral adipose tissue for the identification of cardiometabolic risk in white and African American adults. Am J Clin Nutr. 2013; 97:480-486. doi:10.3945/ajcn.112.047787.
33. Neeland IJ, Turer AT, Ayers C.R., Powell-Wiley TM, Vega GL, Farzaneh-Far R, Grundy S.M., Khera A., McGuire DK, de Lemos JA. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA. 2012; 308:1150-1159. doi:10.1001/2012.jama.11132.
34. Albu JB, Murphy L, Frager D.H., Johnson JA, Pi-Sunyer FX. Visceral fat and race-dependent health risks in obese nondiabetic premenopausal women. Diabetes. 1997; 46:456-462.
35. Conway JM, Yanovski SZ, Avila N.A., Hubbard VS. Visceral adipose tissue differences in black and white women. Am J Clin Nutr. 1995; 61:765-771.
36. Sumner AE, Furtado JD, Courville A.B., Ricks M., Younger-Coleman N, Tulloch-Reid MK, Sacks FM. ApoC-III and visceral adipose tissue contribute to paradoxically normal triglyceride levels in insulin-resistant African-American women. Nutr Metab (Lond). 2013; 10:73. doi:10.1186/1743-7075-10-73.
37. Sumner AE, Micklesfield LK, Ricks M, Tambay A.V., Avila NA, Thomas F, Lambert EV, Levitt N.S., Evans J., Rotimi CN, Tulloch-Reid MK, Goedecke JH. Waist circumference, BMI, and visceral adipose tissue in white women and women of African descent. Obesity (Silver Spring). 2011; 19:671-674. doi:10.1038/oby.2010.201.
38. Katzmarzyk PT, Bray GA, Greenway F.L., Johnson WD, Newton RL Jr, Ravussin E, Ryan DH, Bouchard C. Ethnic-specific BMI and waist circumference thresholds. Obesity (Silver Spring). 2011; 19:1272-1278. doi:10.1038/oby.2010.319.
39. Sumner AE, Sen S, Ricks M., Frempong BA, Sebring NG, Kushner H. Determining the waist circumference in African Americans which best predicts insulin resistance. Obesity (Silver Spring). 2008; 16:841-846. doi:10.1038/oby.2008.11.
40. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies [published correction appears in Lancet. 1004; 363:902].
41. Lancet. 2004; 363:157-163.
42. Alberti KG, Eckel RH, Grundy S.M., Zimmet PZ, Cleeman JI, Donato KA, Fruchart J.C., James WP, Loria CM, Smith SC Jr; International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120:1640-1645. doi:10.1161/CIRCULATIONAHA.109.192644.
43. Go AS, Mozaffarian D, Roger V.L., Benjamin EJ, Berry JD, Borden WB, Bravata D.M., Dai S., Ford ES, Fox CS, Franco S, Fullerton H.J., Gillespie C., Hailpern SM, Heit JA, Howard VJ, Huffman M.D., Kissela BM, Kittner SJ, Lackland DT, Lichtman J.H., Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar D.B., McGuire DK, Mohler ER, Moy CS, Mussolino M.E., Nichol G., Paynter NP, Schreiner PJ, Sorlie PD, Stein J, Turan TN, Virani SS, Wong ND, Woo D, Turner MB; on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics - 2013 update: a report from the American Heart Association. Circulation. 2013; 127:143-152. doi:10.1161/CIR.0b013e318282ab8f.
44. Remaley AT, Amar M, Sviridov D. HDL-replacement therapy: mechanism of action, types of agents and potential clinical indications. Expert Rev Cardiovasc Ther. 2008; 6:1203-1215. doi:10.1586/14779072.6.9.1203.
45. Sumner AE. "Half the dsylipidemia of insulin resistance" is the dyslipidemia [corrected] of insulin-resistant blacks [published correction appears in Ethn Dis. 2010; 20:ii].
46. Ethn Dis. 2009; 19:462-465.
47. Sumner AE, Harman JL, Buxbaum S.G., Miller BV 3rd, Tambay AV, Wyatt SB, Taylor HA, Rotimi CN, Sarpong DF. The triglyceride/high-density lipoprotein cholesterol ratio fails to predict insulin resistance in African-American women: an analysis of Jackson Heart Study. Metab Syndr Relat Disord. 2010; 8:511-514. doi:10.1089/met.2010.0028.
48. Gaillard T, Parthasarathy S, Osei K. HDL dysfunctionality (Paraoxonase) is worse in nondiabetic, postmenopausal African American than in white women. Diabetes Care. 2011; 34:e19. doi:10.2337/dc10-1189.
49. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285:2486-2497.
50. Wenger NK. You've come a long way, baby: cardiovascular health and disease in women: problems and prospects. Circulation. 2004; 109:558-560. doi:10.1161/01.CIR.0000117292.19349.D0.
51. Manson JE, Colditz GA, Stampfer M.J., Willett WC, Krolewski AS, Rosner B, Arky R.A., Speizer FE, Hennekens CH. A prospective study of maturityonset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med. 1991; 151:1141-1147.
52. Juutilainen A, Kortelainen S, Lehto S., Rönnemaa T, Pyörälä K, Laakso M. Gender difference in the impact of type 2 diabetes on coronary heart disease risk. Diabetes Care. 2004; 27:2898-2904.
53. Gu K, Cowie CC, Harris MI Diabetes and decline in heart disease mortality in US adults. JAMA. 1999; 281:1291-1297.
54. Steinberg HO, Paradisi G, Cronin J., Crowde K, Hempfling A, Hook G., Baron AD. Type II diabetes abrogates sex differences in endothelial function in premenopausal women. Circulation. 2000; 101:2040-2046.
55. Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications. 2001; 15:44-54.
56. Grundy SM. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation. 2002; 105:2696-2698.
57. Pradhan AD. Sex differences in the metabolic syndrome: implications for cardiovascular health in women. Clin Chem. 2014; 60:44-52. doi:10.1373/clinchem.2013.202549.
58. Ford ES, Ajani UA, Croft J.B., Critchley JA, Labarthe DR, Kottke TE, Giles W.H., Capewell S. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med. 2007; 356:2388-2398. doi:10.1056/NEJMsa053935.
59. Wexler DJ, Grant RW, Meigs J.B., Nathan DM, Cagliero E. Sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes. Diabetes Care. 2005; 28:514-520.
60. Chou AF, Scholle SH, Weisman C.S., Bierman AS, Correa-de-Araujo R, Mosca L. Gender disparities in the quality of cardiovascular disease care in private managed care plans. Womens Health Issues. 2007; 17:120-130. doi:10.1016/j.whi.2007.03.002.
61. Bird CE, Fremont A, Wickstrom S., Bierman AS, McGlynn E. Improving women's quality of care for cardiovascular disease and diabetes: the feasibility and desirability of stratified reporting of objective performance measures. Womens Health Issues. 2003; 13:150-157.
62. Vaccarino V, Rathore SS, Wenger N.K., Frederick PD, Abramson JL, Barron HV, Manhapra A, Mallik S., Krumholz HM; National Registry of Myocardial Infarction Investigators. Sex and racial differences in the management of acute myocardial infarction, 1994 through 2002. N Engl J Med. 2005; 353:671-682. doi:10.1056/NEJMsa032214.
63. Wenger NK. Coronary heart disease in women: highlights of the past 2 years: stepping stones, milestones and obstructing boulders. Nat Clin Pract Cardiovasc Med. 2006; 3:194-202. doi:10.1038/ncpcardio0516.
64. Nichols GA, Gullion CM, Koro C.E., Ephross SA, Brown JB. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care. 2004; 27:1879-1884.
65. Thrainsdottir IS, Aspelund T, Thorgeirsson G., Gudnason V, Hardarson T, Malmberg K., Sigurdsson G, Rydén L. The association between glucose abnormalities and heart failure in the population-based Reykjavik study. Diabetes Care. 2005; 28:612-616.
66. Kannel WB, Hjortland M, Castelli WP Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974; 34:29-34.
67. Seghieri C, Francesconi P, Cipriani S., Rapanà M, Anichini R, Franconi F, Del Prato S, Seghieri G. Gender effect on the relation between diabetes and hospitalization for heart failure. Exp Clin Endocrinol Diabetes. 2012; 120:51-55. doi:10.1055/s-0031-1284377.
68. Lima R, Wofford M, Reckelhoff JF Hypertension in postmenopausal women. Curr Hypertens Rep. 2012; 14:254-260. doi:10.1007/s11906-012-0260-0.
69. de Burgos-Lunar C, Jiménez-García R, Salinero-Fort MA, Gómez-Campelo P, Gil A, Abánades-Herranz JC, Cárdenas-Valladolid J, del Cura-González I. Trends in hypertension prevalence, awareness, treatment and control in an adult type 2 diabetes Spanish population between 2003 and 2009. PLoS One. 2014; 9:e86713. doi:10.1371/journal.pone.0086713.
70. Donahue RP, Stranges S, Rafalson L., Dmochowski J, Dorn J, Trevisan M. Risk factors for prehypertension in the community: a prospective analysis from the Western New York Health Study. Nutr Metab Cardiovasc Dis. 2014; 24:162-167. doi:10.1016/j.numecd.2013.06.006.
71. Awa WL, Fach E, Krakow D., Welp R, Kunder J, Voll A., Zeyfang A, Wagner C, Schütt M, Boehm B., de Souza M, Holl RW; DPV Initiative; German BMBF Competence Networks Diabetes Mellitus and Obesity. Type 2 diabetes from pediatric to geriatric age: analysis of gender and obesity among 120,183 patients from the German/Austrian DPV database. Eur J Endocrinol. 2012; 167:245-254. doi:10.1530/EJE-12-0143.
72. Novak M, Björck L, Welin L., Welin C, Manhem K, Rosengren A. Gender differences in the prevalence of metabolic syndrome in 50-year-old Swedish men and women with hypertension born in 1953. J Hum Hypertens. 2013; 27:56-61. doi:10.1038/jhh.2011.106.
73. Hall JE, da Silva AA, do Carmo JM, Dubinion J, Hamza S, Munusamy S., Smith G, Stec DE. Obesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortins. J Biol Chem. 2010; 285:17271-17276. doi:10.1074/jbc.R110.113175.
74. da Silva A.A., do Carmo JM, Hall JE. Role of leptin and central nervous system melanocortins in obesity hypertension. Curr Opin Nephrol Hypertens. 2013; 22:135-140. doi:10.1097/MNH.0b013e32835d0c05.
75. Greenfield JR. Melanocortin signalling and the regulation of blood pressure in human obesity. J Neuroendocrinol. 2011; 23:186-193. doi:10.1111/j.1365-2826.2010.02088.x.
76. Bomback AS, Kshirsagar AV, Whaley-Connell AT, Chen S.C., Li S., Klemmer PJ, McCullough PA, Bakris GL. Racial differences in kidney function among individuals with obesity and metabolic syndrome: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2010; 55(Suppl 2):S4-S14. doi:10.1053/j.ajkd.2009.10.045.
77. Babayev R, Whaley-Connell A, Kshirsagar A., Klemmer P, Navaneethan S, Chen S.C., Li S., McCullough PA, Bakris G, Bomback A; KEEP Investigators. Association of race and body mass index with ESRD and mortality in CKD stages 3-4: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2013; 61:404-412. doi:10.1053/j. ajkd.2012.11.038.
78. Silbiger SR, Neugarten J. The role of gender in the progression of renal disease. Adv Ren Replace Ther. 2003; 10:3-14. doi:10.1053/jarr.2003.50001.
79. Doublier S, Lupia E, Catanuto P., Elliot SJ. Estrogens and progression of diabetic kidney damage. Curr Diabetes Rev. 2011; 7:28-34.
80. Moulana M, Lima R, Reckelhoff JF Metabolic syndrome, androgens, and hypertension. Curr Hypertens Rep. 2011; 13:158-162. doi:10.1007/s11906-011-0184-0.
81. James PA, Oparil S, Carter B.L., Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland D.T., LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey L P, Taler SJ, Townsend R.R., Wright JT Jr, Narva AS, Ortiz E. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) [published correction appears in JAMA. 2014; 311:1809].
82. JAMA. 2014; 311:507-520. doi:10.1001/jama.2013.284427.
83. Lopez-Ruiz A., Sartori-Valinotti J, Yanes L.L., Iliescu R., Reckelhoff JF. Sex differences in control of blood pressure: role of oxidative stress in hypertension in females. Am J Physiol Heart Circ Physiol. 2008; 295:H466-H474. doi:10.1152/ajpheart.01232.2007.
84. Nautiyal M, Shaltout HA, de Lima DC, do Nascimento K, Chappell MC, Diz DI Central angiotensin-(1-7) improves vagal function independent of blood pressure in hypertensive (mRen2)27 rats. Hypertension. 2012; 60:1257-1265. doi:10.1161/HYPERTENSIONAHA.112.196782.
85. Ojeda NB, Hennington BS, Williamson D.T., Hill ML, Betson NE, Sartori-Valinotti JC, Reckelhoff JF, Royals T.P., Alexander BT. Oxidative stress contributes to sex differences in blood pressure in adult growth-restricted offspring. Hypertension. 2012; 60:114-122. doi:10.1161/HYPERTENSIONAHA.112.192955.
86. Rexrode KM. Emerging risk factors in women. Stroke. 2010; 41(suppl):S9-S11. doi:10.1161/STROKEAHA.110.595280.
87. Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies [published correction appears in Lancet. 2010; 376:958].
88. Lancet. 2010; 375:2215-2222. doi:10.1016/S0140-6736(10)60484-9.
89. O'Donnell M.J., Xavier D, Liu L., Zhang H, Chin SL, Rao-Melacini P, Rangarajan S., Islam S, Pais P, McQueen M.J., Mondo C., Damasceno A, Lopez-Jaramillo P, Hankey GJ, Dans A.L., Yusoff K., Truelsen T, Diener HC, Sacco R.L., Ryglewicz D., Czlonkowska A, Weimar C, Wang X., Yusuf S; INTERSTROKE Investigators. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010; 376:112-123. doi:10.1016/S0140-6736(10)60834-3.
90. Ohira T, Shahar E, Chambless L.E., Rosamond WD, Mosley TH Jr, Folsom AR. Risk factors for ischemic stroke subtypes: the Atherosclerosis Risk in Communities study. Stroke. 2006; 37:2493-2498. doi:10.1161/01. STR.0000239694.19359.88.
91. Cui R, Iso H, Yamagishi K., Saito I, Kokubo Y, Inoue M., Tsugane S. Diabetes mellitus and risk of stroke and its subtypes among Japanese: the Japan Public Health Center Study. Stroke. 2011; 42:2611-2614. doi:10.1161/STROKEAHA.111.614313.
92. Iso H, Rexrode K, Hennekens C.H., Manson JE. Application of computer tomography-oriented criteria for stroke subtype classification in a prospective study. Ann Epidemiol. 2000; 10:81-87.
93. Giralt D, Domingues-Montanari S, Mendioroz M., Ortega L, Maisterra O, Perea-Gainza M, Delgado P., Rosell A, Montaner J. The gender gap in stroke: a meta-analysis. Acta Neurol Scand. 2012; 125:83-90. doi:10.1111/j.1600-0404.2011.01514.x.
94. Kannel WB, McGee DL Diabetes and cardiovascular disease: the Framingham study. JAMA. 1979; 241:2035-2038.
95. Tanizaki Y, Kiyohara Y, Kato I., Iwamoto H, Nakayama K, Shinohara N., Arima H, Tanaka K, Ibayashi S., Fujishima M. Incidence and risk factors for subtypes of cerebral infarction in a general population: the Hisayama study. Stroke. 2000; 31:2616-2622.
96. Hyvärinen M., Tuomilehto J, Laatikainen T., Söderberg S, Eliasson M., Nilsson P, Qiao Q. The impact of diabetes on coronary heart disease differs from that on ischaemic stroke with regard to the gender. Cardiovasc Diabetol. 2009; 8:17. doi:10.1186/1475-2840-8-17.
97. Doi Y, Ninomiya T, Hata J., Fukuhara M, Yonemoto K, Iwase M., Iida M, Kiyohara Y. Impact of glucose tolerance status on development of ischemic stroke and coronary heart disease in a general Japanese population: the Hisayama study. Stroke. 2010; 41:203-209. doi:10.1161/STROKEAHA.109.564708.
98. Peters SA, Huxley RR, Woodward M. Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. Lancet. 2014; 383:1973-1980. doi:10.1016/S0140-6736(14)60040-4.
99. Bushnell C, McCullough LD, Awad I.A., Chireau MV, Fedder WN, Furie KL, Howard V.J., Lichtman JH, Lisabeth LD, Piña IL, Reeves M.J., Rexrode KM, Saposnik G, Singh V, Towfighi A., Vaccarino V, Walters MR; on behalf of the American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Council for High Blood Pressure Research. Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association/American Stroke Association [published correction appears in Stroke. 2014; 45:e214
100. Stroke. 2014; 45:e95].
101. Stroke. 2014; 45:1545-1588. doi:10.1161/01.str.0000442009.06663.48.
102. Eriksson M, Carlberg B, Eliasson M. The disparity in long-term survival after a first stroke in patients with and without diabetes persists: the Northern Sweden MONICA study. Cerebrovasc Dis. 2012; 34:153-160. doi:10.1159/000339763.
103. Ho JE, Paultre F, Mosca L; Women's Pooling Project. Is diabetes mellitus a cardiovascular disease risk equivalent for fatal stroke in women? Data from the Women's Pooling Project. Stroke. 2003; 34:2812-2816. doi:10.1161/01.STR.0000102901.41780.5C.
104. Janghorbani M, Hu FB, Willett W.C., Li TY, Manson JE, Logroscino G, Rexrode KM Prospective study of type 1 and type 2 diabetes and risk of stroke subtypes: the Nurses' Health Study. Diabetes Care. 2007; 30:1730-1735. doi:10.2337/dc06-2363.
105. Zhao W, Katzmarzyk PT, Horswell R, Wang Y., Johnson J, Hu G. Sex differences in the risk of stroke and HbA(1c) among diabetic patients. Diabetologia. 2014; 57:918-926. doi:10.1007/s00125-014-3190-3.
106. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, SimonsMorton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358:2545-59.
107. American Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care. 2003; 26:3333-3341.
108. Murabito JM, Evans JC, Nieto K, Larson M.G., Levy D., Wilson PW. Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am Heart J. 2002; 143:961-965.
109. Higgins JP, Higgins JA Epidemiology of peripheral arterial disease in women. J Epidemiol. 2003; 13:1-14.
110. Brevetti G, Bucur R, Balbarini A., Melillo E, Novo S, Muratori I., Chiariello M. Women and peripheral arterial disease: same disease, different issues. J Cardiovasc Med (Hagerstown). 2008; 9:382-388. doi:10.2459/JCM.0b013e3282f03b90.
111. Criqui MH, Denenberg JO, Langer R.D., Fronek A. The epidemiology of peripheral arterial disease: importance of identifying the population at risk. Vasc Med. 1997; 2:221-226.
112. Kannel WB, McGee DL Update on some epidemiologic features of intermittent claudication: the Framingham Study. J Am Geriatr Soc. 1985; 33:13-18.
113. Brand FN, Abbott RD, Kannel WB Diabetes, intermittent claudication, and risk of cardiovascular events: the Framingham Study. Diabetes. 1989; 38:504-509.
114. Kumakura H, Kanai H, Araki Y., Kasama S, Sumino H, Ito T., Iwasaki T, Takayama Y, Ichikawa S., Fujita K, Nakashima K, Minami K. Sex-related differences in Japanese patients with peripheral arterial disease. Atherosclerosis. 2011; 219:846-850. doi:10.1016/j. atherosclerosis.2011.08.037.
115. Tseng CH. Sex difference in the distribution of atherosclerotic risk factors and their association with peripheral arterial disease in Taiwanese type 2 diabetic patients. Circ J. 2007; 71:1131-1136.
116. Wisman PP, Tangelder MJ, van Hattum ES, de Borst GJ, Moll FL. Young women with PAD are at high risk of cardiovascular complications. Eur J Vasc Endovasc Surg. 2012; 43:441-445. doi:10.1016/j.ejvs.2012.01.006.
117. Gardner AW, Parker DE, Montgomery P.S., Blevins SM. Diabetic women are poor responders to exercise rehabilitation in the treatment of claudication. J Vasc Surg. 2014; 59:1036-1043. doi:10.1016/j.jvs.2013.10.058.
118. Magnant JG, Cronenwett JL, Walsh D.B., Schneider JR, Besso SR, Zwolak RM. Surgical treatment of infrainguinal arterial occlusive disease in women. J Vasc Surg. 1993; 17:67-76.
119. Azziz R, Woods KS, Reyna R, Key T.J., Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004; 89:2745-2749. doi:10.1210/jc.2003-032046.
120. Carmina E, Azziz R. Diagnosis, phenotype, and prevalence of polycystic ovary syndrome. Fertil Steril. 2006; 86(suppl 1):S7-S8. doi:10.1016/j.fertnstert.2006.03.012.
121. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W., Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998; 83:3078-3082. doi:10.1210/jcem.83.9.5090.
122. Chang AY, Ayers C, Minhajuddin A., Jain T, Nurenberg P, de Lemos JA, Wild RA, Auchus RJ. Polycystic ovarian syndrome and subclinical atherosclerosis among women of reproductive age in the Dallas Heart Study. Clin Endocrinol (Oxf). 2011; 74:89-96. doi:10.1111/j.1365-2265.2010.03907.x.
123. Lauritsen MP, Bentzen JG, Pinborg A, Loft A., Forman JL, Thuesen LL, Cohen A, Hougaard D.M., Nyboe Andersen A. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone. Hum Reprod. 2014; 29:791-801. doi:10.1093/humrep/det469.
124. Yildiz BO, Bozdag G, Yapici Z., Esinler I, Yarali H. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod. 2012; 27:3067-3073. doi:10.1093/humrep/des232.
125. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989; 38:1165-1174.
126. Randeva HS, Tan BK, Weickert M.O., Lois K., Nestler JE, Sattar N, Lehnert H. Cardiometabolic aspects of the polycystic ovary syndrome. Endocr Rev. 2012; 33:812-841. doi:10.1210/er.2012-1003.
127. Ehrmann DA, Liljenquist DR, Kasza K, Azziz R., Legro RS, Ghazzi MN; PCOS/Troglitazone Study Group. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006; 91:48-53. doi:10.1210/jc.2005-1329.
128. Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A., Escobar-Morreale HF, Futterweit W, Lobo R., Norman RJ, Talbott E, Dumesic DA. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab. 2010; 95:2038-2049. doi:10.1210/jc.2009-2724.
129. Legro RS, Kunselman AR, Dodson W.C., Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999; 84:165-169. doi:10.1210/jcem.84.1.5393.
130. Ehrmann DA, Barnes RB, Rosenfield R.L., Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999; 22:141-146.
131. Palmert MR, Gordon CM, Kartashov A.I., Legro RS, Emans SJ, Dunaif A. Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab. 2002; 87:1017-1023. doi:10.1210/jcem.87.3.8305.
132. Dahlgren E, Janson PO, Johansson S, Lapidus L., Odén A. Polycystic ovary syndrome and risk for myocardial infarction: evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand. 1992; 71:599-604.
133. Schmidt J, Landin-Wilhelmsen K, Brännström M, Dahlgren E. Cardiovascular disease and risk factors in PCOS women of postmenopausal age: a 21-year controlled follow-up study. J Clin Endocrinol Metab. 2011; 96:3794-3803. doi:10.1210/jc.2011-1677.
134. Iftikhar S, Collazo-Clavell ML, Roger V.L., St Sauver J, Brown RD Jr, Cha S, Rhodes DJ. Risk of cardiovascular events in patients with polycystic ovary syndrome. Neth J Med. 2012; 70:74-80.
135. Wild S, Pierpoint T, McKeigue P., Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf). 2000; 52:595-600.
136. Wild S, Pierpoint T, Jacobs H., McKeigue P. Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study. Hum Fertil (Camb). 2000; 3:101-105.
137. Solomon CG, Hu FB, Dunaif A, Rich-Edwards JE, Stampfer M.J., Willett WC, Speizer FE, Manson JE. Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab. 2002; 87:2013-2017. doi:10.1210/jcem.87.5.8471.
138. Krentz AJ, von Mühlen D, Barrett-Connor E. Searching for polycystic ovary syndrome in postmenopausal women: evidence of a doseeffect association with prevalent cardiovascular disease. Menopause. 2007; 14:284-292. doi:10.1097/GME.0b013e31802cc7ab.
139. Wang ET, Cirillo PM, Vittinghoff E, Bibbins-Domingo K, Cohn B.A., Cedars MI. Menstrual irregularity and cardiovascular mortality. J Clin Endocrinol Metab. 2011; 96:E114-E118. doi:10.1210/jc.2010-1709.
140. Malik S, Wong ND, Franklin S.S., Kamath TV, L'Italien GJ, Pio JR, Williams GR Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004; 110:1245-1250. doi:10.1161/01. CIR.0000140677.20606.0E.
141. Rutter MK, Meigs JB, Sullivan L.M., D'Agostino RB Sr, Wilson PW. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation. 2004; 110:380-385. doi:10.1161/01.CIR.0000136581.59584.0E.
142. Solomon CG, Hu FB, Dunaif A, Rich-Edwards J, Willett W.C., Hunter DJ, Colditz GA, Speizer FE, Manson JE Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus. JAMA. 2001; 286:2421-2426.
143. Wild RA, Grubb B, Hartz A., Van Nort JJ, Bachman W, Bartholomew M. Clinical signs of androgen excess as risk factors for coronary artery disease. Fertil Steril. 1990; 54:255-259.
144. Shaw LJ, Bairey Merz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein G.D., Kelsey SF, Kip KE, Cooper-Dehoff RM, Johnson BD, Vaccarino V, Reis S.E., Bittner V., Hodgson TK, Rogers W, Pepine CJ. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health-National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation [retraction in J Clin Endocrinol Metab. 2015].
145. J Clin Endocrinol Metab. 2008; 93:1276-1284. doi:10.1210/jc.2007-0425.
146. Welt CK, Carmina E. Clinical review: lifecycle of polycystic ovary syndrome (PCOS): from in utero to menopause. J Clin Endocrinol Metab. 2013; 98:4629-4638. doi:10.1210/jc.2013-2375.
147. Santoro N, Randolph JF Jr. Reproductive hormones and the menopause transition. Obstet Gynecol Clin North Am. 2011; 38:455-466. doi:10.1016/j.ogc.2011.05.004.
148. Spencer JB, Klein M, Kumar A., Azziz R. The age-associated decline of androgens in reproductive age and menopausal black and white women. J Clin Endocrinol Metab. 2007; 92:4730-4733. doi:10.1210/jc.2006-2365.
149. Sowers MF, Zheng H, McConnell D., Nan B, Karvonen-Gutierrez CA, Randolph JF Jr. Testosterone, sex hormone-binding globulin and free androgen index among adult women: chronological and ovarian aging. Hum Reprod. 2009; 24:2276-2285. doi:10.1093/humrep/dep209.
150. Talbott EO, Guzick DS, Sutton-Tyrrell K, McHugh-Pemu KP, Zborowski JV, Remsberg K.E., Kuller LH. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol. 2000; 20:2414-2421.
151. Orio F Jr, Palomba S., Cascella T, De Simone B, Di Biase S, Russo T, Labella D., Zullo F, Lombardi G, Colao A. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004; 89:4588-4593. doi:10.1210/jc.2003-031867.
152. Carmina E, Orio F, Palomba S., Longo RA, Cascella T, Colao A, Lombardi G., Rini GB, Lobo RA. Endothelial dysfunction in PCOS: role of obesity and adipose hormones. Am J Med. 2006; 119:356.e1-356.e6. doi:10.1016/j.amjmed.2005.10.059.
153. Vryonidou A, Papatheodorou A, Tavridou A., Terzi T, Loi V, Vatalas I.A., Batakis N., Phenekos C, Dionyssiou-Asteriou A. Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005; 90:2740-2746. doi:10.1210/jc.2004-2363.
154. Meyer ML, Malek AM, Wild R.A., Korytkowski MT, Talbott EO. Carotid artery intima-media thickness in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2012; 18:112-126. doi:10.1093/humupd/dmr046.
155. Brinkworth GD, Noakes M, Moran L.J., Norman R., Clifton PM. Flow-mediated dilatation in overweight and obese women with polycystic ovary syndrome. BJOG. 2006; 113:1308-1314. doi:10.1111/j.1471-0528.2006.01090.x.
156. Kahal H, Aburima A, Ungvari T., Rigby AS, Dawson AJ, Coady AM, Vince R.V., Ajjan RA, Kilpatrick ES, Naseem KM, Atkin SL Polycystic ovary syndrome has no independent effect on vascular, inflammatory or thrombotic markers when matched for obesity. Clin Endocrinol (Oxf). 2013; 79:252-258. doi:10.1111/cen.12137.
157. Sprung VS, Atkinson G, Cuthbertson D.J., Pugh CJ, Aziz N, Green DJ, Cable N.T., Jones H. Endothelial function measured using flow-mediated dilation in polycystic ovary syndrome: a meta-analysis of the observational studies. Clin Endocrinol (Oxf). 2013; 78:438-446. doi:10.1111/j.1365-2265.2012.04490.x.
158. Talbott EO, Zborowski JV, Boudreaux M.Y., McHugh-Pemu KP, Sutton-Tyrrell K, Guzick DS. The relationship between C-reactive protein and carotid intima-media wall thickness in middle-aged women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004; 89:6061-6067. doi:10.1210/jc.2003-032110.
159. Dokras A, Jagasia DH, Maifeld M, Sinkey C.A., VanVoorhis BJ, Haynes WG. Obesity and insulin resistance but not hyperandrogenism mediates vascular dysfunction in women with polycystic ovary syndrome. Fertil Steril. 2006; 86:1702-1709. doi:10.1016/j.fertnstert.2006.05.038.
160. Meyer C, McGrath BP, Cameron J, Kotsopoulos D., Teede HJ. Vascular dysfunction and metabolic parameters in polycystic ovary syndrome. J Clin Endocrinol Metab. 2005; 90:4630-4635. doi:10.1210/jc.2004-1487.
161. Paradisi G, Steinberg HO, Hempfling A, Cronin J., Hook G, Shepard MK, Baron AD Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation. 2001; 103:1410-1415.
162. Diamanti-Kandarakis E., Alexandraki K, Protogerou A., Piperi C, Papamichael C, Aessopos A., Lekakis J, Mavrikakis M. Metformin administration improves endothelial function in women with polycystic ovary syndrome. Eur J Endocrinol. 2005; 152:749-756. doi:10.1530/eje.1.01910.
163. Tarkun I, Arslan BC, Cantürk Z, Türemen E, Sahin T., Duman C. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab. 2004; 89:5592-5596. doi:10.1210/jc.2004-0751.
164. Christian RC, Dumesic DA, Behrenbeck T, Oberg A.L., Sheedy PF 2nd, Fitzpatrick LA. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003; 88:2562-2568. doi:10.1210/jc.2003-030334.
165. Shroff R, Kerchner A, Maifeld M., Van Beek EJ, Jagasia D, Dokras A. Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis. J Clin Endocrinol Metab. 2007; 92:4609-4614. doi:10.1210/jc.2007-1343.
166. Talbott EO, Zborowski JV, Rager J.R., Boudreaux MY, Edmundowicz DA, Guzick DS. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004; 89:5454-5461. doi:10.1210/jc.2003-032237.
167. Calderon-Margalit R., Siscovick D, Merkin S.S., Wang E., Daviglus ML, Schreiner PJ, Sternfeld B, Williams O.D., Lewis CE, Azziz R, Schwartz SM, Wellons MF Prospective association of polycystic ovary syndrome with coronary artery calcification and carotid-intima-media thickness: the Coronary Artery Risk Development in Young Adults Women's study. Arterioscler Thromb Vasc Biol. 2014; 34:2688-2694. doi:10.1161/ATVBAHA.114.304136.
168. Loria CM, Liu K, Lewis C.E., Hulley SB, Sidney S, Schreiner PJ, Williams O.D., Bild DE, Detrano R. Early adult risk factor levels and subsequent coronary artery calcification: the CARDIA Study. J Am Coll Cardiol. 2007; 49:2013-2020. doi:10.1016/j.jacc.2007.03.009.
169. Jain T, Peshock R, McGuire D.K., Willett D., Yu Z, Vega GL, Guerra R, Hobbs H.H., Grundy SM; Dallas Heart Study Investigators. African Americans and Caucasians have a similar prevalence of coronary calcium in the Dallas Heart Study [published correction appears in J Am Coll Cardiol. 2004; 44:1936].
170. J Am Coll Cardiol. 2004; 44:1011-1017. doi:10.1016/j.jacc.2004.05.069.
171. Greenland P, Alpert JS, Beller G.A., Benjamin EJ, Budoff MJ, Fayad ZA, Foster E, Hlatky M.A., Hodgson JM, Kushner FG, Lauer MS, Shaw L.J., Smith SC Jr, Taylor AJ, Weintraub WS, Wenger NK, Jacobs AK 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2010; 122:2748-2764. doi:10.1161/CIR.0b013e3182051bab.
172. Shah BR, Retnakaran R, Booth GL Increased risk of cardiovascular disease in young women following gestational diabetes mellitus. Diabetes Care. 2008; 31:1668-1669. doi:10.2337/dc08-0706.
173. Carr DB, Utzschneider KM, Hull R.L., Tong J., Wallace TM, Kodama K, Shofer JB, Heckbert S.R., Boyko EJ, Fujimoto WY, Kahn SE. Gestational diabetes mellitus increases the risk of cardiovascular disease in women with a family history of type 2 diabetes. Diabetes Care. 2006; 29:2078-2083. doi:10.2337/dc05-2482.
174. Mosca L, Benjamin EJ, Berra K, Bezanson J.L., Dolor RJ, Lloyd-Jones DM, Newby LK, Piña IL, Roger V.L., Shaw LJ, Zhao D, Beckie TM, Bushnell C, D'Armiento J, Kris-Etherton PM, Fang J., Ganiats TG, Gomes AS, Gracia CR, Haan C.K., Jackson EA, Judelson DR, Kelepouris E, Lavie C.J., Moore A., Nussmeier NA, Ofili E, Oparil S, Ouyang P., Pinn VW, Sherif K, Smith SC Jr, Sopko G, Chandra-Strobos N, Urbina EM, Vaccarino V, Wenger NK. Effectiveness-based guidelines for the prevention of cardiovascular disease in women - 2011 update: a guideline from the American Heart Association [published correction appears in Circulation. 2011; 123:e624
175. Circulation. 2011; 124:e427].
176. Circulation. 2011; 123:1243-1262. doi:10.1161/CIR.0b013e31820faaf8.
177. Kessous R, Shoham-Vardi I, Pariente G., Sherf M, Sheiner E. An association between gestational diabetes mellitus and long-term maternal cardiovascular morbidity. Heart. 2013; 99:1118-1121. doi:10.1136/heartjnl-2013-303945.
178. Fadl H, Magnuson A, Östlund I, Montgomery S, Hanson U, Schwarcz E. Gestational diabetes mellitus and later cardiovascular disease: a Swedish population based case-control study. BJOG. 2014; 121:1530-1536. doi:10.1111/1471-0528.12754.
179. Pallardo LF, Herranz L, Martin-Vaquero P, Garcia-Ingelmo T, Grande C, Jañez M. Impaired fasting glucose and impaired glucose tolerance in women with prior gestational diabetes are associated with a different cardiovascular profile. Diabetes Care. 2003; 26:2318-2322.
180. Rivero K, Portal VL, Vieira M, Behle I. Prevalence of the impaired glucose metabolism and its association with risk factors for coronary artery disease in women with gestational diabetes. Diabetes Res Clin Pract. 2008; 79:433-437. doi:10.1016/j.diabres.2007.10.015.
181. Kousta E, Efstathiadou Z, Lawrence N.J., Jeffs JA, Godsland IF, Barrett SC, Doré CJ, Penny A, Anyaoku V, Millauer BA, Cela E, Robinson S, McCarthy MI, Johnston DG. The impact of ethnicity on glucose regulation and the metabolic syndrome following gestational diabetes. Diabetologia. 2006; 49:36-40. doi:10.1007/s00125-005-0058-6.
182. Pallardo F, Herranz L, Garcia-Ingelmo T, Grande C., Martin-Vaquero P, Jañez M, Gonzalez A. Early postpartum metabolic assessment in women with prior gestational diabetes. Diabetes Care. 1999; 22:1053-1058.
183. Cho NH, Jang HC, Park H.K., Cho YW. Waist circumference is the key risk factor for diabetes in Korean women with history of gestational diabetes. Diabetes Res Clin Pract. 2006; 71:177-183. doi:10.1016/j. diabres.2005.06.003.
184. Xiang AH, Kawakubo M, Kjos S.L., Buchanan TA. Long-acting injectable progestin contraception and risk of type 2 diabetes in Latino women with prior gestational diabetes mellitus. Diabetes Care. 2006; 29:613-617.
185. Heitritter SM, Solomon CG, Mitchell G.F., Skali-Ounis N, Seely EW. Subclinical inflammation and vascular dysfunction in women with previous gestational diabetes mellitus. J Clin Endocrinol Metab. 2005; 90:3983-3988. doi:10.1210/jc.2004-2494.
186. Bo S, Valpreda S, Menato G., Bardelli C, Botto C, Gambino R., Rabbia C, Durazzo M, Cassader M., Massobrio M, Pagano G. Should we consider gestational diabetes a vascular risk factor? Atherosclerosis. 2007; 194:e72-e79. doi:10.1016/j.atherosclerosis.2006.09.017.
187. Brewster S, Zinman B, Retnakaran R., Floras JS. Cardiometabolic consequences of gestational dysglycemia. J Am Coll Cardiol. 2013; 62:677-684. doi:10.1016/j.jacc.2013.01.080.
188. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339:229-234. doi:10.1056/NEJM199807233390404.
189. Grundy SM, Howard B, Smith S Jr, Eckel R, Redberg R, Bonow RO Prevention Conference VI: Diabetes and Cardiovascular Disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation. 2002; 105:2231-2239.
190. Schramm TK, Gislason GH, Køber L, Rasmussen S, Rasmussen JN, Abildstrøm SZ, Hansen ML, Folke F, Buch P, Madsen M, Vaag A, Torp-Pedersen C. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation. 2008; 117:1945-1954. doi:10.1161/CIRCULATIONAHA.107.720847.
191. Legro RS, Gnatuk CL, Kunselman A.R., Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab. 2005; 90:3236-3242. doi:10.1210/jc.2004-1843.
192. Boudreaux MY, Talbott EO, Kip K.E., Brooks MM, Witchel SF. Risk of T2DM and impaired fasting glucose among PCOS subjects: results of an 8-year follow-up. Curr Diab Rep. 2006; 6:77-83.
193. Talbott EO, Zborowski JV, Rager J.R., Kip KE, Xu X, Orchard TJ. Polycystic ovarian syndrome (PCOS): a significant contributor to the overall burden of type 2 diabetes in women. J Womens Health (Larchmt). 2007; 16:191-197. doi:10.1089/jwh.2006.0098.
194. Wang ET, Calderon-Margalit R, Cedars M.I., Daviglus ML, Merkin SS, Schreiner PJ, Sternfeld B, Wellons M., Schwartz SM, Lewis CE, Williams OD, Siscovick D.S., Bibbins-Domingo K. Polycystic ovary syndrome and risk for long-term diabetes and dyslipidemia. Obstet Gynecol. 2011; 117:6-13. doi:10.1097/AOG.0b013e31820209bb.
195. Moran LJ, Misso ML, Wild R.A., Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2010; 16:347-363. doi:10.1093/humupd/dmq001.
196. Bellamy L, Casas JP, Hingorani A.D., Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet. 2009; 373:1773-1779. doi:10.1016/S0140-6736(09)60731-5.
197. Boomsma CM, Eijkemans MJ, Hughes E.G., Visser GH, Fauser BC, Macklon NS. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update. 2006; 12:673-683. doi:10.1093/humupd/dm1036.
198. Toulis KA, Goulis DG, Kolibianakis E.M., Venetis CA, Tarlatzis BC, Papadimas I. Risk of gestational diabetes mellitus in women with polycystic ovary syndrome: a systematic review and a meta-analysis. Fertil Steril. 2009; 92:667-677. doi:10.1016/j.fertnstert.2008.06.045.
199. Lakhani K, Leonard A, Seifalian A.M., Hardiman P. Microvascular dysfunction in women with polycystic ovary syndrome. Hum Reprod. 2005; 20:3219-3224. doi:10.1093/humrep/dei199.
200. Kravariti M, Naka KK, Kalantaridou S.N., Kazakos N., Katsouras CS, Makrigiannakis A, Paraskevaidis EA, Chrousos G.P., Tsatsoulis A., Michalis LK. Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005; 90:5088-5095. doi:10.1210/jc.2005-0151.
201. Palomba S, Falbo A, Zullo F., Orio F Jr. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev. 2009; 30:1-50. doi:10.1210/er.2008-0030.
202. Jensterle M, Janez A, Mlinar B., Marc J, Prezelj J, Pfeifer M. Impact of metformin and rosiglitazone treatment on glucose transporter 4 mRNA expression in women with polycystic ovary syndrome. Eur J Endocrinol. 2008; 158:793-801. doi:10.1530/EJE-07-0857.
203. Teede HJ, Meyer C, Hutchison S.K., Zoungas S., McGrath BP, Moran LJ. Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy. Fertil Steril. 2010; 93:184-191. doi:10.1016/j.fertnstert.2008.09.034.
204. Essah PA, Arrowood JA, Cheang K.I., Adawadkar SS, Stovall DW, Nestler JE. Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. Fertil Steril. 2011; 96:501-504.e2. doi:10.1016/j.fertnstert.2011.05.091.
205. Meyer C, McGrath BP, Teede HJ Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care. 2007; 30:471-478. doi:10.2337/dc06-0618.
206. Studen KB, Sebestjen M, Pfeifer M., Prezelj J. Influence of spironolactone treatment on endothelial function in non-obese women with polycystic ovary syndrome. Eur J Endocrinol. 2011; 164:389-395. doi:10.1530/EJE-10-0709.
207. Hedderson MM, Xu F, Darbinian J.A., Quesenberry CP, Sridhar S, Kim C, Gunderson E.P., Ferrara A. Prepregnancy SHBG concentrations and risk for subsequently developing gestational diabetes mellitus. Diabetes Care. 2014; 37:1296-1303. doi:10.2337/dc13-1965.
208. Vejrazkova D, Vcelak J, Vankova M., Lukasova P, Bradnova O, Halkova T., Kancheva R, Bendlova B. Steroids and insulin resistance in pregnancy. J Steroid Biochem Mol Biol. 2014; 139:122-129. doi:10.1016/j. jsbmb.2012.11.007.
209. Kerr A, Exeter D, Hanham G., Grey C, Zhao J, Riddell T., Lee M, Jackson R, Wells S. Effect of age, gender, ethnicity, socioeconomic status and region on dispensing of CVD secondary prevention medication in New Zealand: the Atlas of Health Care Variation CVD cohort (VIEW-1). N Z Med J. 2014; 127:39-69.
210. Hart S, Smith CM, Swash M. Word fluency in patients with early dementia of Alzheimer type [published correction appears in Br J Clin Psychol. 1988; 27(pt 4):392].
211. Br J Clin Psychol. 1988; 27(pt 2):115-124.
212. Lauffenburger JC, Robinson JG, Oramasionwu C, Fang G. Racial/ethnic and gender gaps in the use of and adherence to evidence-based preventive therapies among elderly Medicare Part D beneficiaries after acute myocardial infarction. Circulation. 2014; 129:754-763. doi:10.1161/CIRCULATIONAHA.113.002658.
213. Vimalananda VG, Miller DR, Hofer T.P., Holleman RG, Klamerus ML, Kerr EA. Accounting for clinical action reduces estimates of gender disparities in lipid management for diabetic veterans. J Gen Intern Med. 2013; 28(Suppl 2):S529-S535. doi:10.1007/s11606-013-2340-5.
214. Selmer R, Sakshaug S, Skurtveit S., Furu K, Tverdal A. Statin treatment in a cohort of 20 212 men and women in Norway according to cardiovascular risk factors and level of education. Br J Clin Pharmacol. 2009; 67:355-362. doi:10.1111/j.1365-2125.2008.03360.x.
215. Lewey J, Shrank WH, Bowry A.D., Kilabuk E., Brennan TA, Choudhry NK. Gender and racial disparities in adherence to statin therapy: a meta-analysis. Am Heart J. 2013; 165:665-678, 678.e1. doi:10.1016/j.ahj.2013.02.011.
216. Yu MK, Lyles CR, Bent-Shaw LA, Young BA. Sex disparities in diabetes process of care measures and self-care in high-risk patients. J Diabetes Res. 2013; 2013:575814. doi:10.1155/2013/575814.
217. Ruokoniemi P, Sund R, Arffman M., Helin-Salmivaara A, Huupponen R, Keskimäki I, Vehko T., Korhonen MJ. Are statin trials in diabetes representative of real-world diabetes care: a population-based study on statin initiators in Finland. BMJ Open. 2014; 4:e005402. doi:10.1136/bmjopen-2014-005402.
218. Kern DM, Balu S, Tunceli O., Anzalone D. Statin treatment patterns and clinical profile of patients with risk factors for coronary heart disease defined by National Cholesterol Education Program Adult Treatment Panel III. Curr Med Res Opin. 2014; 30:2443-2451.
219. Stone NJ, Robinson JG, Lichtenstein A.H., Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D., Lloyd-Jones DM, McBride P, Schwartz J.S., Shero ST, Smith SC Jr, Watson K, Wilson PW, Eddleman K.M., Jarrett NM, LaBresh K, Nevo L, Wnek J., Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis R.G., Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in Circulation. 2014; 129(suppl 2):S46-S48].
220. Circulation. 2014; 129(suppl 2):S1-S45. doi: 10.1161/01.cir.0000437738.63853.7a.
221. Johansson I, Dahlstrom U, Edner M, Nasman P, Ryden L, Norhammar A. Risk factors, treatment, and prognosis in men and women with heart failure with and without diabetes. Heart. 2015; 101:1139-1148. doi:10.1136/heartjnl-2014-307131.
222. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376:1670-1681. doi:10.1016/S0140-6736(10)61350-5.
223. Puri R, Nissen SE, Shao M, Ballantyne C.M., Barter PJ, Chapman MJ, Erbel R, Libby P., Raichlen JS, Uno K, Kataoka Y, Nicholls SJ Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy: insights from SATURN. JACC Cardiovasc Imaging. 2014; 7:1013-1022. doi:10.1016/j. jcmg.2014.04.019.
224. Ferrara A, Mangione CM, Kim C, Marrero D.G., Curb D., Stevens M, Selby JV; Translating Research Into Action for Diabetes Study Group. Sex disparities in control and treatment of modifiable cardiovascular disease risk factors among patients with diabetes: Translating Research Into Action for Diabetes (TRIAD) Study. Diabetes Care. 2008; 31:69-74. doi:10.2337/dc07-1244.
225. Sattar N, Preiss D, Murray H.M., Welsh P., Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema J.W., Macfarlane PW, Packard CJ, Stott DJ, Westendorp R.G., Shepherd J., Davis BR, Pressel SL, Marchioli R, Marfisi R.M., Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J., Pedersen TR, Cook TJ, Gotto AM, Clearfield M.B., Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010; 375:735-742. doi:10.1016/S0140-6736(09)61965-6.
226. Aiman U, Najmi A, Khan RA Statin induced diabetes and its clinical implications. J Pharmacol Pharmacother. 2014; 5:181-185. doi:10.4103/0976-500X.136097.
227. Goldfine AB. Statins: is it really time to reassess benefits and risks? N Engl J Med. 2012; 366:1752-1755. doi:10.1056/NEJMp1203020.
228. Smiderle L, Lima LO, Hutz M.H., Van der Sand CR, Van der Sand LC, Ferreira ME, Pires RC, Almeida S, Fiegenbaum M. Evaluation of sexual dimorphism in the efficacy and safety of simvastatin/atorvastatin therapy in a southern Brazilian cohort. Arq Bras Cardiol. 2014; 103:33-40.
229. d'Emden M.C., Jenkins AJ, Li L, Zannino D., Mann KP, Best JD, Stuckey BG, Park K, Saltevo J., Keech AC; FIELD Study Investigators. Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study [published correction appears in Diabetologia. 2015; 58:2200].
230. Diabetologia. 2014; 57:2296-2303. doi:10.1007/s00125-014-3344-3.
231. Hodis HN, Mack WJ The timing hypothesis and hormone replacement therapy: a paradigm shift in the primary prevention of coronary heart disease in women, part 1: comparison of therapeutic efficacy. J Am Geriatr Soc. 2013; 61:1005-1010. doi:10.1111/jgs.12140.
232. Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009; 373:1849-1860. doi:10.1016/S0140-6736(09)60503-1.
233. Ridker PM, Cook NR, Lee I.M., Gordon D., Gaziano JM, Manson JE, Hennekens CH, Buring JE A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005; 352:1293-1304. doi:10.1056/NEJMoa050613.
234. Belch J, MacCuish A, Campbell I., Cobbe S, Taylor R, Prescott R., Lee R, Bancroft J, MacEwan S., Shepherd J, Macfarlane P, Morris A., Jung R, Kelly C, Connacher A., Peden N, Jamieson A, Matthews D., Leese G, McKnight J, O'Brien I, Semple C, Petrie J, Gordon D, Pringle S, MacWalter R; Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh. The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008; 337:a1840.
235. Ogawa H, Nakayama M, Morimoto T., Uemura S, Kanauchi M, Doi N., Jinnouchi H, Sugiyama S, Saito Y; Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial [published correction appears in JAMA. 2009; 301:1882
236. published correction appears in JAMA. 2012; 308:1861.
237. JAMA. 2008; 300:2134-2141. doi:10.1001/jama.2008.623.
238. Aspirin effects on mortality and morbidity in patients with diabetes mellitus: Early Treatment Diabetic Retinopathy Study Report 14: ETDRS Investigators. JAMA. 1992; 268:1292-1300.
239. Simpson SH, Gamble JM, Mereu L, Chambers T. Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta-analysis. J Gen Intern Med. 2011; 26:1336-1344. doi:10.1007/s11606-011-1757-y.
240. Calvin AD, Aggarwal NR, Murad M.H., Shi Q., Elamin MB, Geske JB, Fernandez-Balsells MM, Albuquerque FN, Lampropulos J.F., Erwin PJ, Smith SA, Montori VM. Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes. Diabetes Care. 2009; 32:2300-2306. doi:10.2337/dc09-1297.
241. Zhang C, Sun A, Zhang P., Wu C, Zhang S, Fu M., Wang K, Zou Y, Ge J. Aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract. 2010; 87:211-218. doi:10.1016/j.diabres.2009.09.029.
242. Younis N, Williams S, Ammori B., Soran H. Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis. Expert Opin Pharmacother. 2010; 11:1459-1466. doi:10.1517/14656561003792538.
243. De Berardis G., Sacco M, Strippoli G.F., Pellegrini F., Graziano G, Tognoni G, Nicolucci A. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials [published correction appears in BMJ. 2010; 340:c374].
244. BMJ. 2009; 339:b4531.
245. Pignone M, Alberts MJ, Colwell J.A., Cushman M., Inzucchi SE, Mukherjee D, Rosenson RS, Williams C.D., Wilson PW, Kirkman MS. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation. 2010; 121:2694-2701. doi:10.1161/CIR.0b013e3181e3b133.
246. Kitzmiller JL, Block JM, Brown F.M., Catalano PM, Conway DL, Coustan DR, Gunderson E.P., Herman WH, Hoffman LD, Inturrisi M, Jovanovic L.B., Kjos SI, Knopp RH, Montoro MN, Ogata E.S., Paramsothy P., Reader DM, Rosenn BM, Thomas AM, Kirkman MS Managing preexisting diabetes for pregnancy: summary of evidence and consensus recommendations for care. Diabetes Care. 2008; 31:1060-1079. doi:10.2337/dc08-9020.
247. Langer O, Conway DL, Berkus M.D., Xenakis EM, Gonzales O. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med. 2000; 343:1134-1138. doi:10.1056/NEJM200010193431601.
248. Refuerzo JS. Oral hypoglycemic agents in pregnancy. Obstet Gynecol Clin North Am. 2011; 38:227-234, ix. doi:10.1016/j.ogc.2011.02.013.
249. Rowan JA, Hague WM, Gao W, Battin M.R., Moore MP; MiG Trial Investigators. Metformin versus insulin for the treatment of gestational diabetes [published correction appears in N Engl J Med. 2008; 359:106].
250. N Engl J Med. 2008; 358:2003-2015. doi:10.1056/NEJMoa0707193.
251. Feig DS, Moses RG Metformin therapy during pregnancy: good for the goose and good for the gosling too? Diabetes Care. 2011; 34:2329-2330. doi:10.2337/dc11-1153.
252. Gilbert C, Valois M, Koren G. Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. Fertil Steril. 2006; 86:658-663. doi:10.1016/j.fertnstert.2006.02.098.
253. National Institute for Health and Clinical Excellence (NICE). Diabetes in pregnancy: management of diabetes and its complications from preconception to the postnatal period. 2008. http://www.nice.org.uk/nicemedia/pdf/CG063NICEGuideline.pdf. Accessed August 1, 2013.
254. Edison RJ, Muenke M. Central nervous system and limb anomalies in case reports of first-trimester statin exposure [published correction appears in N Engl J Med. 2005; 352:2759].
255. N Engl J Med. 2004; 350:1579-1582. doi:10.1056/NEJM200404083501524.
256. Winterfeld U, Allignol A, Panchaud A., Rothuizen LE, Merlob P, Cuppers-Maarschalkerweerd B, Vial T, Stephens S., Clementi M, De Santis M, Pistelli A, Berlin M., Eleftheriou G, Maňáková E, Buclin T. Pregnancy outcome following maternal exposure to statins: a multicentre prospective study. BJOG. 2013; 120:463-471. doi:10.1111/1471-0528.12066.
257. Costantine MM, Cleary K; Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetric-Fetal Pharmacology Research Units Network. Pravastatin for the prevention of preeclampsia in high-risk pregnant women. Obstet Gynecol. 2013; 121(pt 1):349-353. doi: http://10.1097/AOG.0b013e31827d8ad5.
258. Bullo M, Tschumi S, Bucher B.S., Bianchetti MG, Simonetti GD. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. Hypertension. 2012; 60:444-450. doi:10.1161/HYPERTENSIONAHA.112.196352.
259. Alabdulrazzaq F, Koren G. Fetal safety of calcium channel blockers. Can Fam Physician. 2012; 58:746-747.
260. Yakoob MY, Bateman BT, Ho E, Hernandez-Diaz S, Franklin J.M., Goodman JE, Hoban RA. The risk of congenital malformations associated with exposure to β-blockers early in pregnancy: a meta-analysis. Hypertension. 2013; 62:375-381. doi:10.1161/HYPERTENSIONAHA.111.00833.
261. Orbach H, Matok I, Gorodischer R., Sheiner E, Daniel S, Wiznitzer A., Koren G, Levy A. Hypertension and antihypertensive drugs in pregnancy and perinatal outcomes. Am J Obstet Gynecol. 2013; 208:301.e1-301.e6. doi:10.1016/j.ajog.2012.11.011.
262. American Diabetes Association. Standards of Medical Care in Diabetes-2014. Diabetes Care. 2014; 37(suppl 1):S14-S80.
263. Jakicic JM, Egan CM, Fabricatore A.N., Gaussoin SA, Glasser SP, Hesson LA, Knowler W.C., Lang W., Regensteiner JG, Ribisl PM, Ryan DH; Look AHEAD Research Group. Four-year change in cardiorespiratory fitness and influence on glycemic control in adults with type 2 diabetes in a randomized trial: the Look AHEAD Trial. Diabetes Care. 2013; 36:1297-1303. doi:10.2337/dc12-0712.
264. Look AHEAD Research Group, Pi-Sunyer X, Blackburn G, Brancati FL, Bray GA, Bright R, Clark JM, Curtis JM, Espeland MA, Foreyt JP, Graves K, Haffner SM, Harrison B, Hill JO, Horton ES, Jakicic J, Jeffery RW, Johnson KC, Kahn S, Kelley DE, Kitabchi AE, Knowler WC, Lewis CE, Maschak-Carey BJ, Montgomery B, Nathan DM, Patricio J, Peters A, Redmon JB, Reeves RS, Ryan DH, Safford M, Van Dorsten B, Wadden TA, Wagenknecht L, Wesche-Thobaben J, Wing RR, Yanovski SZ. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the Look AHEAD Trial. Diabetes Care. 2007; 30:1374-1383.
265. Andrews RC, Cooper AR, Montgomery A.A., Norcross AJ, Peters TJ, Sharp DJ, Jackson N, Fitzsimons K., Bright J, Coulman K, England C.Y., Gorton J., McLenaghan A, Paxton E, Polet A., Thompson C, Dayan CM. Diet or diet plus physical activity versus usual care in patients with newly diagnosed type 2 diabetes: the Early ACTID randomised controlled trial. Lancet. 2011; 378:129-139. doi:10.1016/S0140-6736(11)60442-X.
266. Boulé NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA. 2001; 286:1218-1227.
267. Castaneda C, Layne JE, Munoz-Orians L, Gordon P.L., Walsmith J., Foldvari M, Roubenoff R, Tucker K.L., Nelson ME. A randomized controlled trial of resistance exercise training to improve glycemic control in older adults with type 2 diabetes. Diabetes Care. 2002; 25:2335-2341.
268. Brassard P, Legault S, Garneau C., Bogaty P, Dumesnil JG, Poirier P. Normalization of diastolic dysfunction in type 2 diabetics after exercise training [published correction appears in Med Sci Sports Exerc. 2008; 40:400].
269. Med Sci Sports Exerc. 2007; 39:1896-1901. doi:10.1249/mss.0b013e318145b642.
270. Lee DC, Sui X, Church T.S., Lavie CJ, Jackson AS, Blair SN. Changes in fitness and fatness on the development of cardiovascular disease risk factors hypertension, metabolic syndrome, and hypercholesterolemia. J Am Coll Cardiol. 2012; 59:665-672. doi:10.1016/j. jacc.2011.11.013.
271. Balducci S, Zanuso S, Nicolucci A., De Feo P, Cavallo S, Cardelli P., Fallucca S, Alessi E, Fallucca F., Pugliese G; Italian Diabetes Exercise Study (IDES) Investigators. Effect of an intensive exercise intervention strategy on modifiable cardiovascular risk factors in subjects with type 2 diabetes mellitus: a randomized controlled trial: the Italian Diabetes and Exercise Study (IDES). Arch Intern Med. 2010; 170:1794-1803. doi:10.1001/archinternmed.2010.380.
272. Sone H, Tanaka S, Iimuro S., Tanaka S, Oida K, Yamasaki Y., Oikawa S, Ishibashi S, Katayama S., Yamashita H, Ito H, Yoshimura Y., Ohashi Y, Akanuma Y, Yamada N; Japan Diabetes Complications Study Group. Long-term lifestyle intervention lowers the incidence of stroke in Japanese patients with type 2 diabetes: a nationwide multicentre randomised controlled trial (the Japan Diabetes Complications Study). Diabetologia. 2010; 53:419-428. doi:10.1007/s00125-009-1622-2.
273. Look AHEAD Research Group, Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, Crow RS, Curtis JM, Egan CM, Espeland MA, Evans M, Foreyt JP, Ghazarian S, Gregg EW, Harrison B, Hazuda HP, Hill JO, Horton ES, Hubbard VS, Jakicic JM, Jeffery RW, Johnson KC, Kahn SE, Kitabchi AE, Knowler WC, Lewis CE, Maschak-Carey BJ, Montez MG, Murillo A, Nathan DM, Patricio J, Peters A, Pi-Sunyer X, Pownall H, Reboussin D, Regensteiner JG, Rickman AD, Ryan DH, Safford M, Wadden TA, Wagenknecht LE, West DS, Williamson DF, Yanovski SZ. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes [published correction appears in N Engl J Med. 2014; 370:1866].
274. N Engl J Med. 2013; 369:145-154.
275. Larose J, Sigal RJ, Boulé NG, Wells GA, Prud'homme D, Fortier MS, Reid RD, Tulloch H, Coyle D, Phillips P, Jennings A, Khandwala F, Kenny GP. Effect of exercise training on physical fitness in type II diabetes mellitus. Med Sci Sports Exerc. 2010; 42:1439-1447. doi:10.1249/MSS.0b013e3181d322dd.
276. Saaristo T, Moilanen L, Korpi-Hyövälti E, Vanhala M, Saltevo J, Niskanen L, Jokelainen J, Peltonen M, Oksa H, Tuomilehto J, Uusitupa M, Keinänen-Kiukaanniemi S. Lifestyle intervention for prevention of type 2 diabetes in primary health care: one-year follow-up of the Finnish National Diabetes Prevention Program (FIN-D2D). Diabetes Care. 2010; 33:2146-2151. doi:10.2337/dc10-0410.
277. Perreault L, Ma Y, Dagogo-Jack S, Horton E., Marrero D, Crandall J, Barrett-Connor E; Diabetes Prevention Program. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care. 2008; 31:1416-1421. doi:10.2337/dc07-2390.
278. Li G, Zhang P, Wang J., An Y, Gong Q, Gregg E.W., Yang W., Zhang B, Shuai Y, Hong J., Engelgau MM, Li H, Roglic G, Hu Y., Bennett PH. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol. 2014; 2:474-480. doi:10.1016/S2213-8587(14)70057-9.
279. Church TS, Cheng YJ, Earnest C.P., Barlow CE, Gibbons LW, Priest EL, Blair SN Exercise capacity and body composition as predictors of mortality among men with diabetes. Diabetes Care. 2004; 27:83-88.
280. Lyerly GW, Sui X, Lavie C.J., Church TS, Hand GA, Blair SN. The association between cardiorespiratory fitness and risk of all-cause mortality among women with impaired fasting glucose or undiagnosed diabetes mellitus. Mayo Clin Proc. 2009; 84:780-786. doi:10.1016/S0025-6196(11)60487-4.
281. McAuley PA, Myers JN, Abella J.P., Tan SY, Froelicher VF. Exercise capacity and body mass as predictors of mortality among male veterans with type 2 diabetes. Diabetes Care. 2007; 30:1539-1543. doi:10.2337/dc06-2397.
282. Lee DC, Sui X, Artero E.G., Lee IM, Church TS, McAuley PA, Stanford F.C., Kohl HW 3rd, Blair SN. Long-term effects of changes in cardiorespiratory fitness and body mass index on all-cause and cardiovascular disease mortality in men: the Aerobics Center Longitudinal Study. Circulation. 2011; 124:2483-2490. doi:10.1161/CIRCULATIONAHA.111.038422.
283. Jakicic JM, Jaramillo SA, Balasubramanyam A, Bancroft B., Curtis JM, Mathews A, Pereira M, Regensteiner J.G., Ribisl PM; Look AHEAD Study Group. Effect of a lifestyle intervention on change in cardiorespiratory fitness in adults with type 2 diabetes: results from the Look AHEAD Study. Int J Obes (Lond). 2009; 33:305-316. doi:10.1038/ijo.2008.280.
284. Nielsen PJ, Hafdahl AR, Conn V.S., Lemaster JW, Brown SA. Metaanalysis of the effect of exercise interventions on fitness outcomes among adults with type 1 and type 2 diabetes. Diabetes Res Clin Pract. 2006; 74:111-120. doi:10.1016/j.diabres.2006.03.033.
285. Conn VS, Hafdahl AR, Lemaster J.W., Ruppar TM, Cochran JE, Nielsen PJ. Meta-analysis of health behavior change interventions in type 1 diabetes. Am J Health Behav. 2008; 32:315-329. doi:10.5555/ajhb.2008.32.3.315.
286. Conn VS, Hafdahl AR, Mehr D.R., LeMaster JW, Brown SA, Nielsen PJ. Metabolic effects of interventions to increase exercise in adults with type 2 diabetes. Diabetologia. 2007; 50:913-921. doi:10.1007/s00125-007-0625-0.
287. MacLeod SF, Terada T, Chahal B.S., Boulé NG. Exercise lowers postprandial glucose but not fasting glucose in type 2 diabetes: a meta-analysis of studies using continuous glucose monitoring. Diabetes Metab Res Rev. 2013; 29:593-603. doi:10.1002/dmrr.2461.
288. Norris SL, Zhang X, Avenell A., Gregg E, Brown TJ, Schmid C.H., Lau J. Long-term non-pharmacologic weight loss interventions for adults with type 2 diabetes. Cochrane Database Syst Rev. 2005:CD004095.
289. Fredriksson J, Anevski D, Almgren P., Sjögren M, Lyssenko V., Carlson J, Isomaa B, Taskinen M.R., Groop L., Orho-Melander M; Botnia Study Group. Variation in GYS1 interacts with exercise and gender to predict cardiovascular mortality. PLoS One. 2007; 2:e285. doi:10.1371/journal.pone.0000285.
290. Sadarangani K.P., Hamer M, Mindell J.S., Coombs NA, Stamatakis E. Physical activity and risk of all-cause and cardiovascular disease mortality in diabetic adults from Great Britain: pooled analysis of 10 population-based cohorts. Diabetes Care. 2014; 37:1016-1023. doi:10.2337/dc13-1816.
291. Zhang Y, Post WS, Blasco-Colmenares E, Dalal D., Tomaselli GF, Guallar E. Electrocardiographic QT interval and mortality: a meta-analysis. Epidemiology. 2011; 22:660-670. doi:10.1097/EDE.0b013e318225768b.
292. Cox AJ, Azeem A, Yeboah J., Soliman EZ, Aggarwal SR, Bertoni AG, Carr J.J., Freedman BI, Herrington DM, Bowden DW. Heart rate-corrected QT interval is an independent predictor of all-cause and cardiovascular mortality in individuals with type 2 diabetes: the Diabetes Heart Study. Diabetes Care. 2014; 37:1454-1461. doi:10.2337/dc13-1257.
293. Giunti S, Bruno G, Lillaz E., Gruden G, Lolli V, Chaturvedi N., Fuller JH, Veglio M, Cavallo-Perin P; EURODIAB IDDM Complications Study Group. Incidence and risk factors of prolonged QTc interval in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care. 2007; 30:2057-2063. doi:10.2337/dc07-0063.
294. Ruppert K, Roberts MS, Orchard T.J., Zgibor JC. Cardiovascular disease risk prediction in type 1 diabetes: accounting for the differences. Diabetes Res Clin Pract. 2007; 78:234-237. doi:10.1016/j.diabres.2007.03.008.
295. Hu FB, Stampfer MJ, Solomon C, Liu S., Colditz GA, Speizer FE, Willett WC, Manson JE Physical activity and risk for cardiovascular events in diabetic women. Ann Intern Med. 2001; 134:96-105.
296. Physical Activity Guidelines Committee. Physical Activity Guidelines Committee Report, 2008. Washington, DC: US Department of Health and Human Services; 2008.
297. Colberg SR, Albright AL, Blissmer B.J., Braun B., Chasan-Taber L, Fernhall B, Regensteiner J.G., Rubin RR, Sigal RJ; American College of Sports Medicine; American Diabetes Association. Exercise and type 2 diabetes: American College of Sports Medicine and the American Diabetes Association: joint position statement: exercise and type 2 diabetes. Med Sci Sports Exerc. 2010; 42:2282-2303. doi:10.1249/MSS.0b013e3181eeb61c.